Tirzepatide's Dual Mechanism vs Single GLP-1 Agonists

Tirzepatide

22.5% body weight lost

Participants taking the highest dose of tirzepatide in the SURMOUNT-1 trial lost an average of 22.5% of their body weight over 72 weeks, exceeding results from any single GLP-1 agonist.

Jastreboff et al., NEJM, 2022

Jastreboff et al., NEJM, 2022

View as image

Tirzepatide does something no approved GLP-1 agonist does alone: it activates two incretin receptors simultaneously. By binding both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, tirzepatide produces weight loss and blood sugar reduction that consistently exceeds what single GLP-1 agonists achieve. In the SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks.^[1] In the SURPASS-2 head-to-head trial, tirzepatide outperformed semaglutide 1 mg on every measure of glycemic control and weight loss.^[2] Understanding why requires looking at what GIP adds to the equation. For more on how tirzepatide affects body composition, including the critical question of muscle loss, see our pillar article.

Two Incretins, Not One

To understand tirzepatide, you first need to understand the two hormones it mimics. GLP-1 and GIP are both incretin hormones, released by the gut after eating. They both stimulate insulin secretion. But they do it through different receptors on different cell populations, and they have different effects beyond the pancreas.

Seino et al. (2010) published the foundational comparison of these two hormones, documenting their similarities and key differences.^[3] GLP-1 is released from L-cells in the ileum and colon. GIP is released from K-cells in the duodenum and jejunum, meaning it responds to food earlier in the digestive process. Both hormones are rapidly degraded by the enzyme DPP-4, giving them half-lives of only 2-3 minutes in their natural forms.

The critical difference: GLP-1 suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying, and reduces appetite through brain signaling. GIP does not suppress glucagon and does not slow gastric emptying. Instead, GIP improves insulin sensitivity in adipose tissue, promotes fat storage efficiency, and appears to have direct effects on bone metabolism.^[3]

For decades, the GLP-1 pathway got all the attention. GIP was considered irrelevant or even counterproductive for diabetes treatment because its insulinotropic effect is impaired in type 2 diabetes patients. Tirzepatide changed that perspective. For a comprehensive comparison of every GLP-1 receptor agonist currently available, see our class overview.

The Synergy Effect: Why Two Receptors Beat One

Bergmann et al. (2019) provided direct evidence for synergy between GIP and GLP-1. In a randomized crossover study, they infused healthy volunteers with GIP alone, GLP-1 alone, or both hormones combined, then measured the effects on insulin response, appetite, and energy expenditure.^[4]

The combined infusion produced an insulin response that was significantly greater than the sum of each hormone's individual effect. This is not additive; it is synergistic, meaning the two hormones amplify each other through their parallel receptor pathways. The combined infusion also reduced energy intake at a subsequent meal more than either hormone alone.

This synergy is the mechanistic rationale for tirzepatide's existence. A drug that activates both pathways simultaneously should, in theory, produce effects greater than even the most potent single GLP-1 agonist. The clinical trials confirmed this theory.

Structural Design: How Tirzepatide Activates Two Receptors

Zhao et al. (2022) solved the crystal structures of tirzepatide bound to both the GIP and GLP-1 receptors, publishing the results in Nature Communications.^[5] The structural analysis revealed that tirzepatide is not a 50/50 agonist. It is approximately five-fold more potent at the GIP receptor than at the GLP-1 receptor.

Tirzepatide is a 39-amino-acid peptide based on the native GIP sequence, with modifications that confer GLP-1 receptor binding capability. A C20 fatty acid chain attached to lysine at position 20 enables albumin binding, extending the half-life to approximately 5 days (compared to 2-3 minutes for native GIP or GLP-1). This long half-life allows once-weekly dosing.

The imbalanced receptor potency is deliberate. Min et al. (2021) reviewed the design rationale, noting that the stronger GIP component drives unique metabolic effects (improved insulin sensitivity, lipid metabolism) while the GLP-1 component provides appetite suppression and gastric emptying delay that GIP alone cannot achieve.^[6]

Head-to-Head: Tirzepatide vs Semaglutide

The SURPASS-2 trial, published in the New England Journal of Medicine by Frias et al. (2021), provided the first direct comparison. In 1,879 patients with type 2 diabetes inadequately controlled on metformin, tirzepatide at 5, 10, or 15 mg was compared to semaglutide 1 mg weekly.^[2]

At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.07% compared to 1.86% for semaglutide 1 mg. Weight loss with tirzepatide 15 mg averaged 11.2 kg compared to 5.7 kg with semaglutide. All three tirzepatide doses were statistically noninferior to semaglutide for HbA1c reduction, and the 10 mg and 15 mg doses were statistically superior.

The gastrointestinal side effect profiles were comparable between tirzepatide and semaglutide, with nausea, diarrhea, and vomiting occurring at similar rates. This suggests that the additional GIP component does not worsen the tolerability issues associated with GLP-1 receptor activation. The nausea and vomiting that patients experience with these drugs is primarily mediated by GLP-1 receptor activation in the area postrema of the brainstem. Since tirzepatide is less potent at the GLP-1 receptor than at GIP, some researchers hypothesized it might cause less nausea per unit of efficacy, though the clinical data shows similar tolerability profiles when comparing equivalent weight loss outcomes.

Nauck et al. (2022) analyzed the full evidence across the SURPASS program, confirming that tirzepatide's glycemic efficacy is "unmatched" compared to existing diabetes treatments, including all single GLP-1 agonists.^[7] A detailed comparison of tirzepatide versus semaglutide for weight loss is available in our sibling article.

The Weight Loss Data: SURMOUNT-1

Jastreboff et al. (2022) published the SURMOUNT-1 results, testing tirzepatide specifically for obesity (not diabetes). In 2,539 adults with BMI 30 or higher (or 27 with a weight-related comorbidity), tirzepatide 15 mg produced 22.5% mean body weight loss at 72 weeks compared to 3.1% with placebo.^[1]

These numbers exceeded the weight loss seen in semaglutide's comparable STEP trials (approximately 15-17% at similar timepoints). The additional 5-7 percentage points of weight loss may be attributable to GIP receptor activation, which appears to improve energy expenditure and fat metabolism through pathways that GLP-1 alone does not engage. The complete breakdown of tirzepatide dose-response data and the full SURMOUNT evidence base are covered in dedicated sibling articles.

What GIP Adds Beyond GLP-1

Improved Beta-Cell Function and Insulin Sensitivity

Thomas et al. (2021) analyzed the distinct metabolic effects of tirzepatide versus semaglutide, finding that tirzepatide improved both beta-cell function (how well the pancreas produces insulin) and insulin sensitivity (how well tissues respond to insulin).^[8] Semaglutide primarily improved beta-cell function. The insulin sensitivity improvement is attributed to GIP receptor activation, which has direct effects on adipose tissue insulin signaling.

This dual improvement in both insulin production and insulin action is a key differentiator. A patient with type 2 diabetes has both insufficient insulin secretion and insufficient insulin response. Tirzepatide addresses both defects; GLP-1-only drugs primarily address the secretion defect.

Lipid and Metabolite Effects

Pirro et al. (2022) analyzed tirzepatide's effects on lipid profiles and metabolites, finding improvements in triglycerides, apolipoprotein C-III, and markers of liver fat beyond what GLP-1-only agonists typically achieve.^[9] GIP receptors are expressed on hepatocytes, and GIP signaling appears to directly influence hepatic lipid metabolism. The reduction in liver fat is clinically relevant because nonalcoholic fatty liver disease (NAFLD) is common in patients with type 2 diabetes and obesity.

The Phase 2 Foundation

The clinical development of tirzepatide began with the phase 2 trial published by Frias et al. (2018), which first demonstrated that dual GIP/GLP-1 agonism produced dose-dependent reductions in HbA1c and body weight exceeding those of dulaglutide (a single GLP-1 agonist used as the comparator).^[10] This trial established proof-of-concept that the dual mechanism translated from preclinical synergy data to actual patient outcomes. The phase 2 results were striking enough that Eli Lilly moved rapidly into the phase 3 SURPASS and SURMOUNT programs, which together enrolled over 20,000 patients across multiple countries and generated the evidence base that led to global regulatory approvals.

Limitations and Open Questions

Tirzepatide has not been compared head-to-head against semaglutide 2.4 mg (the obesity-indicated dose). The SURPASS-2 comparison used semaglutide 1 mg (the diabetes dose). Whether tirzepatide maintains its superiority against higher-dose semaglutide is unknown, though cross-trial comparisons suggest it likely does given the magnitude of the differences.

The long-term cardiovascular outcomes data for tirzepatide are still maturing. Semaglutide has demonstrated cardiovascular event reduction in the SELECT trial; tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Until it reports, the cardiovascular safety comparison between dual and single incretin agonism remains incomplete.

The question of what happens to body composition during weight loss on tirzepatide, specifically the ratio of fat loss to muscle loss, is addressed in our pillar article. The concern about muscle loss with rapid weight loss applies to all potent weight loss agents, including tirzepatide.

GIP's role in bone metabolism raises theoretical concerns about long-term bone density effects. GIP receptors are expressed on osteoblasts, and GIP signaling promotes bone formation. Whether pharmacological GIP activation through tirzepatide has meaningful effects on fracture risk during weight loss (when bone loss is expected) has not been adequately studied. Paradoxically, GIP-mediated bone protection could be a benefit rather than a risk, potentially offsetting the bone mineral density losses that typically accompany rapid weight reduction. This would represent an advantage of dual agonism over pure GLP-1 approaches, but the data to confirm or refute this hypothesis does not yet exist.

The commercial distinction between Mounjaro and Zepbound, tirzepatide's two brand names for diabetes and obesity respectively, is covered in our sibling article. Understanding which product is prescribed depends on the indication, and insurance coverage differs between the two.

The Bottom Line

Tirzepatide activates both GIP and GLP-1 receptors, producing weight loss (22.5% in SURMOUNT-1) and glycemic control (2.07% HbA1c reduction in SURPASS-2) that exceeds single GLP-1 agonists. The GIP component adds insulin sensitivity improvement, enhanced lipid metabolism, and liver fat reduction that GLP-1-only drugs do not provide. Structural analysis shows tirzepatide is five-fold more potent at the GIP receptor than the GLP-1 receptor, and combined GIP/GLP-1 infusion studies confirm synergistic rather than merely additive effects. Long-term cardiovascular outcomes and bone metabolism effects remain under investigation.

Frequently Asked Questions

How is tirzepatide different from semaglutide?

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates only GLP-1. In the SURPASS-2 head-to-head trial, tirzepatide 15 mg produced greater HbA1c reduction (2.07% vs 1.86%) and nearly double the weight loss (11.2 kg vs 5.7 kg) compared to semaglutide 1 mg over 40 weeks.^[2] The additional GIP activation improves insulin sensitivity and lipid metabolism beyond what GLP-1 alone achieves.

What is GIP and why does it matter for weight loss?

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released from K-cells in the upper intestine after eating. It stimulates insulin secretion, improves insulin sensitivity in fat tissue, and influences energy metabolism. Combined GIP and GLP-1 infusion produces synergistically greater insulin and appetite responses than either hormone alone.^[4]

How much weight can you lose on tirzepatide?

In the SURMOUNT-1 trial, adults with obesity lost an average of 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) of their body weight over 72 weeks.^[1] These are averages; individual results vary based on dose, starting weight, diet, and exercise. The 22.5% average at the highest dose exceeds published results for any single GLP-1 agonist.

Does tirzepatide have worse side effects than GLP-1 drugs?

The SURPASS-2 trial found comparable gastrointestinal side effect rates between tirzepatide and semaglutide. Nausea, diarrhea, and vomiting occurred at similar frequencies.^[2] The additional GIP component does not appear to worsen tolerability. Dose escalation protocols (starting low and increasing gradually) help minimize initial gastrointestinal side effects with both drug classes.

Is tirzepatide better for type 2 diabetes than semaglutide?

In the SURPASS-2 trial, tirzepatide 10 and 15 mg were statistically superior to semaglutide 1 mg for HbA1c reduction. Thomas et al. (2021) showed tirzepatide improves both beta-cell function and insulin sensitivity, while semaglutide primarily improves beta-cell function alone.^[8] However, the comparison used semaglutide 1 mg, not the higher doses now available.

What is the structure of tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer GLP-1 receptor binding. A C20 fatty acid chain attached at lysine-20 enables albumin binding, extending the half-life to approximately 5 days for once-weekly dosing. Zhao et al. (2022) showed it is five-fold more potent at the GIP receptor than the GLP-1 receptor.^[5]